03:38 , Jan 11, 2019 |  BC Innovations  |  Product R&D

PureTech turns inward

After a 15-year run of spinning out technologies into affiliate companies, PureTech Health plc is stepping away from that model in favor of an internal pipeline to advance its new platforms. Behind the structural shift...
15:00 , Mar 8, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers Tumor levels of PD-L1 , LGALS9 and XAGE-1b proteins could help predict survival in lung adenocarcinoma patients. In 120 patients, high tumor levels of PD-L1, low tumor levels of LGALS9 and low...
08:00 , Jan 29, 2015 |  BC Innovations  |  Strategy

PD-1 matchmaking

The rush to find combinations of PD-1 inhibitors and established cancer therapies marks the end of the beginning, rather than the beginning of the end, of the search for ways to extend use of checkpoint...
07:00 , Jul 31, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Asthma; multiple sclerosis (MS) Galectin-9 (LGALS9); tumor necrosis factor receptor superfamily member 9 (TNFRSF9; 4-1BB; CD137) Mouse and in vitro studies suggest LGALS9 is required...
08:00 , Nov 10, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Influenza virus Galectin-9 (LGALS9) Mouse studies suggest blocking LGALS9 signaling could improve immune responses to influenza vaccines. In mice infected with influenza A virus,...
08:00 , Jan 22, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Galectin-1 (LGALS1); LGALS3; LGALS7; LGALS9 Binding assays and cell culture studies identified thiodigalactoside ester derivatives that inhibit cancer-related galectins and...